Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors, Virtual, United States (21/09/2021–21/09/2021) has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for 1 European CME credit (ECMEC®). Specialists should claim only those hours of credit that are commensurate with their participation in the activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the conversion process can be found at

Live educational activities occurring outside of Canada that are recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1), as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation in the event once he/she has completed the feedback form. See criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC®s per day: 21.09.2021 - 1.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME, with a maximum of 8 ECMEC®s per day. See Chapter X of UEMS 2016.20.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Daiichi Sankyo.

Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors

Release Date: November 30, 2021
Expiration Date: November 30, 2022

Activity Overview

Antibody-drug conjugates (ADCs) comprise a monoclonal antibody linked to a cytotoxic agent that targets tumor cells while sparing healthy cells. Currently, 3 ADCs targeting HER2 and TROP2 are approved for the treatment of patients with solid tumors, and several others are in various stages of development in clinical trials. Adverse events commonly associated with ADCs include interstitial lung disease, which require prompt interventions and mitigation strategies so that patients are able to derive optimal benefit from their therapies without interruptions or discontinuations.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from a live virtual symposium held on September 21, 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of utilizing ADCs for the management of breast, gastrointestinal (GI), and lung cancers, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Daiichi Sankyo.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward a global audience of medical oncologists, pathologists, and fellows interested in the treatment of cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of patients with cancer are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain the mechanistic rationale concerning the role of antibody-drug conjugates (ADCs) in solid tumors
  • Implement best practices for HER2 diagnostic testing to facilitate molecular characterization and selection of HER2-directed therapies in patients with solid tumors
  • Describe ongoing clinical trials and emerging efficacy and safety trial data on the application of novel ADCs in the treatment of patients with solid tumors
  • Formulate strategies to integrate novel ADC approaches into clinical practice for the treatment of patients with solid tumors

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Program Chair

Anthony Mato, MD, MSCE
Cristina Saura, MD, PhD
Head, Breast Cancer Unit
Medical Oncology Service
Vall d’Hebron University Hospital
Barcelona, Spain

Disclosures: Consultant: F. Hoffmann-La Roche & Co, Pfizer Inc, Puma Biotechnology


Claudio Cerchione, MD, PhD
Yelena Y. Janjigian, MD
Associate Professor
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures:Grant/Research Support: Bayer, Bristol Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly and Co, Fred’s Team, Genentech/Roche, Merck & Co, National Cancer Institute, Rgenix. Consultant: AstraZeneca, Basilea Pharmaceutica AG Pharma, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Co, Imugene Ltd, Merck & Co, Merck Serono, Pfizer, Rgenix, Seattle Genetics, Zymeworks Inc. Shareholder: Rgenix (stock options).

Hagop M. Kantarjian, MD
Maurice Pérol, MD
Head of Thoracic Oncology Program
Léon Bérard Cancer Centre
Lyon, France

Disclosures: Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Chugai Pharma USA Inc, Roche, Takeda. Consultant: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly and Co, GlaxoSmithKline, Gritstone bio, F. Hoffmann-La Roche & Co, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Inc, Laboratoires Pierre Fabre, Sanofi Genzyme, Takeda. Speaker’s Bureau: Amgen Inc, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharma USA Inc, Eli Lilly and Co, F. Hoffmann-La Roche & Co, Illumina Inc., Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Inc, Takeda. Travel: AstraZeneca, F. Hoffmann-La Roche & Co., Pfizer Inc, Takeda.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By